Trial Profile
A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 03 May 2011 Planned End Date changed from 1 Dec 2010 to 1 Aug 2011 added as reported by ClinicalTrials.gov.
- 01 Nov 2010 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.